Galectin Therapeutics
GALT
80 hedge funds and large institutions have $34.4M invested in Galectin Therapeutics in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 9 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 19
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
5% more funds holding
Funds holding: 76 → 80 (+4)
1.33% more ownership
Funds ownership: 15.25% → 16.58% (+1.3%)
3% less capital invested
Capital invested by funds: $35.4M → $34.4M (-$932K)
43% less call options, than puts
Call options by funds: $665K | Put options by funds: $1.17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$1.28M |
| 2 |
BlackRock
New York
|
+$910K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$290K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$285K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$186K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$605K |
| 2 |
Renaissance Technologies
New York
|
-$144K |
| 3 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$121K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
-$110K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$72K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RE
76
RBC Europe
London,
United Kingdom
| $147 | – | – | – |
|
|
77
Renaissance Technologies
New York
| – | -$144K | -34,732 | Closed |
|
|
BAM
78
Belpointe Asset Management
Reno,
Nevada
| – | -$121K | -29,228 | Closed |
|
|
CS
79
Credit Suisse
Zurich,
Switzerland
| – | -$72K | -17,384 | Closed |
|
|
IGGA
80
Iron Gate Global Advisors
Nsl,
Utah
| – | -$71K | -17,090 | Closed |
|
81
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
| – | -$57K | -13,727 | Closed |
|
82
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$35K | -8,330 | Closed |
|
|
DWA
83
Dougherty Wealth Advisers
Wayzata,
Minnesota
| – | -$21K | -5,000 | Closed |
|
|
FCMT
84
Founders Capital Management (Texas)
Houston,
Texas
| – | -$4K | -1,000 | Closed |
|
85
Simplex Trading
Chicago,
Illinois
| – | -$3.56K | -986 | Closed |
|
|
MAM
86
Meeder Asset Management
Dublin,
Ohio
| – | +$69 | +19 | New |
|
GALT Hedge Fund Activity: Q3 2019 in Review
80 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2019, worth a combined $34.4M — down 2.6% from $35.4M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new GALT positions and 9 closed out — a net gain of 4 holders — while 29 added to existing stakes and 19 trimmed.
The largest buyer was Northern Trust, adding an estimated $1.28M. The largest seller was Susquehanna International Group, cutting an estimated $605K.
- 80 institutional investors held Galectin Therapeutics (GALT) as of Q3 2019, up from 76 in Q2 2019.
- Funds reported $34.4M of Galectin Therapeutics stock for Q3 2019, down 2.6% quarter-over-quarter.
- 13 funds opened new Galectin Therapeutics positions in Q3 2019 and 9 closed out, a net change of +4 holders.
- The largest Galectin Therapeutics buyer in Q3 2019 was Northern Trust, an estimated $1.28M added.
- The largest Galectin Therapeutics seller in Q3 2019 was Susquehanna International Group, an estimated $605K sold.
Based on aggregated 13F filings for Q3 2019.